-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On Corbus Pharmaceuticals with Buy Rating, Announces Price Target of $45

Benzinga·04/29/2026 16:16:40
Listen to the news
Guggenheim analyst Paul Jeng initiates coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and announces Price Target of $45.